Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis

참고문헌 (12)

1. de Souza HS, "Immunopathogenesis of IBD: current state of the art", Nat Rev Gastroenterol Hepatol, 13, pp.13~27 (2016)
2. Danese S, "Biologic agents for IBD:practical insights", Nat Rev Gastroenterol Hepatol, 12, pp.537~545 (2015)
3. 박성철, "Current and Emerging Biologics for Ulcerative Colitis", Gut and Liver, 9(1), pp.18~27 (2015), 거트앤리버 발행위원회
4. 김은혜, "Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study", Gut and Liver, 9(5), pp.601~606 (2015), 거트앤리버 발행위원회
5. Danese S, "Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis", Ann Intern Med, 160, pp.704~711 (2014)
6. Stidham RW, "Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis", Aliment Pharmacol Ther, 39, pp.660~671 (2014)
7. Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderateto-severe ulcerative colitis", Gastroenterology, 142(e3), pp.257~265 (2012)
8. Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
9. Colombel JF, "Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3", Am J Gastroenterol, 109, pp.1771~1780 (2014)
10. Vavricka SR, "Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)", Inflamm Bowel Dis, 18, pp.1523~1530 (2012)
11. Shomron Ben-Horin, "Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima", Gut, 65(7), pp.1132~1138 (2016), BMJ[DOI]
12. Zong Mei Zhang, "Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials", Gut and Liver, 10(2), pp.262~274 (2016), 거트앤리버 발행위원회

관련 논문AI추천